IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, November 2025
Impact Factor: 7.67

Herbal Nanotechnology in Triple Negative Breast Cancer: A Comprehensive Review

Vaishnavi Rahul Potavale, Miss. Shiba D.Shaikh, Mrudula Gore
Sahakar Maharshi Kisanrao Varal Patil College of Pharmacy, Nighoj

Abstract: *Triple-negative breast cancer (TNBC) represents one of the most aggressive and therapeutically challenging subtypes of breast cancer, characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. The lack of specific molecular targets limits treatment options primarily to cytotoxic chemotherapy, which is often associated with severe side effects and drug resistance. Herbal nanotechnology, an emerging interdisciplinary field combining phytomedicine with nanotechnology, offers promising therapeutic strategies for TNBC management. This review explores the current state of herbal nanoformulations in TNBC treatment, discussing various phytochemicals, nanocarrier systems, mechanisms of action, and future perspectives in this rapidly evolving field.*

Keywords*:* Triple-negative breast cancer, herbal nanotechnology, phytonanomedicine, targeted drug delivery, natural compounds, nanoparticles

I. INTRODUCTION

1.1 Triple Negative Breast Cancer: Clinical Challenge

Triple-negative breast cancer accounts for approximately 15-20% of all breast cancer cases and is characterized by its aggressive nature, early metastasis, high recurrence rates, and poor prognosis (Dent et al., 2007). The absence of ER, PR, and HER2 expression eliminates the possibility of targeted hormonal and HER2-directed therapies, leaving conventional chemotherapy as the primary treatment modality (Foulkes et al., 2010). TNBC predominantly affects younger women and shows higher prevalence in African-American and Hispanic populations (Carey et al., 2006).

The heterogeneous nature of TNBC, with multiple molecular subtypes including basal-like, immunomodulatory, mesenchymal, and luminal androgen receptor subtypes, further complicates therapeutic approaches (Lehmann et al., 2011). Standard chemotherapy regimens, while initially effective, often lead to treatment resistance, systemic toxicity, and disease recurrence, necessitating novel therapeutic strategies.

1.2 Limitations of Conventional TNBC Therapy

Current TNBC treatment protocols face several challenges:

- **Limited targeted therapy options** due to absence of specific receptors
- **Systemic toxicity** from high-dose chemotherapy affecting normal tissues
- **Development of multidrug resistance** through various mechanisms
- **Poor bioavailability** of many chemotherapeutic agents
- **Lack of tumor selectivity** leading to off-target effects
- **High recurrence rates** particularly within the first 3-5 years post-treatment

1.3 Herbal Medicine and Nanotechnology Convergence

Herbal medicines have been used for centuries in various traditional systems including Ayurveda, Traditional Chinese Medicine, and others. Many modern anticancer drugs, including paclitaxel, vincristine, and camptothecin derivatives, are derived from natural sources (Cragg & Newman, 2005). Phytochemicals demonstrate multiple anticancer mechanisms including apoptosis induction, cell cycle arrest, anti-angiogenesis, and modulation of signaling pathways (Greenwell & Rahman, 2015).

However, herbal compounds face significant challenges including poor water solubility, low bioavailability, rapid metabolism, and lack of tumor specificity. Nanotechnology offers solutions to these limitations through:

- **Enhanced solubility and stability** of hydrophobic compounds
- **Improved pharmacokinetics** and biodistribution
- **Controlled and sustained release** of therapeutic agents
- **Enhanced cellular uptake** and intracellular delivery
- **Tumor-specific targeting** through surface modifications
- **Reduced systemic toxicity** through selective accumulation

II. NANOTECHNOLOGY PLATFORMS FOR HERBAL DRUG DELIVERY

2.1 Types of Nanocarrier Systems

2.1.1 Liposomes and Lipid-Based Nanoparticles

Liposomes are spherical vesicles composed of lipid bilayers that can encapsulate both hydrophilic and hydrophobic compounds. They offer excellent biocompatibility and biodegradability (Akbarzadeh et al., 2013). Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) provide advantages of controlled release and improved stability.

Example: Curcumin-loaded liposomes have demonstrated enhanced cytotoxicity in MDA-MB-231 TNBC cells with IC50 values significantly lower than free curcumin (Li et al., 2012).

2.1.2 Polymeric Nanoparticles

Polymeric nanoparticles utilize biodegradable polymers such as PLGA (poly lactic-co-glycolic acid), PLA (polylactic acid), chitosan, and alginate. These systems offer versatile drug loading, controlled release kinetics, and surface modification possibilities (Danhier et al., 2012).

Example: PLGA nanoparticles loaded with resveratrol showed enhanced anticancer activity against TNBC cells through improved cellular uptake and sustained drug release (Singh et al., 2014).

2.1.3 Polymeric Micelles

Polymeric micelles are self-assembled nanostructures formed by amphiphilic block copolymers with a hydrophobic core and hydrophilic shell. They are particularly suitable for encapsulating poorly water-soluble phytochemicals (Cabral et al., 2011).

2.1.4 Dendrimers

Dendrimers are highly branched, monodisperse macromolecules with well-defined structure. PAMAM (polyamidoamine) dendrimers are commonly used for drug delivery with multiple functional groups for drug conjugation and targeting ligand attachment (Svenson & Tomalia, 2005).

2.1.5 Metallic Nanoparticles

Gold nanoparticles (AuNPs), silver nanoparticles (AgNPs), and other metallic nanoparticles can be functionalized with herbal compounds. They offer unique optical properties, ease of synthesis, and biocompatibility (Dreaden et al., 2012).

2.1.6 Mesoporous Silica Nanoparticles

Mesoporous silica nanoparticles (MSNs) provide high surface area, tunable pore size, excellent biocompatibility, and capacity for surface functionalization (Tang et al., 2012).

2.1.7 Nanoemulsions

Oil-in-water or water-in-oil nanoemulsions improve solubility and absorption of lipophilic phytochemicals with droplet sizes typically ranging from 20-200 nm (McClements, 2012).

2.2 Targeting Strategies

2.2.1 Passive Targeting

The enhanced permeability and retention (EPR) effect allows nanoparticles (typically 10-200 nm) to preferentially accumulate in tumor tissues due to leaky tumor vasculature and impaired lymphatic drainage (Maeda et al., 2000).

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, November 2025
Impact Factor: 7.67

2.2.2 Active Targeting

Surface modification with targeting ligands enables specific recognition of receptors overexpressed on TNBC cells:

- **Folic acid** - targets folate receptors
- **Transferrin** - targets transferrin receptors
- **RGD peptides** - target integrins
- **Hyaluronic acid** - targets CD44 receptors
- **Aptamers** - specific nucleic acid ligands
- **Antibodies** - specific protein recognition

2.2.3 Stimuli-Responsive Systems

Smart nanocarriers respond to tumor microenvironment characteristics:

- **pH-responsive** - exploit acidic tumor pH (6.5-7.0)
- **Redox-responsive** - respond to elevated glutathione levels
- **Enzyme-responsive** - activated by tumor-associated enzymes
- **Temperature-responsive** - triggered by hyperthermia
- **Light-responsive** - activated by specific wavelengths

III. HERBAL COMPOUNDS IN TNBC NANOTECHNOLOGY

3.1 Curcumin (Diferuloylmethane)

Curcumin, derived from *Curcuma longa*, is one of the most extensively studied phytochemicals in cancer therapy. It exhibits pleiotropic anticancer effects through multiple mechanisms.

Mechanisms in TNBC:

- Inhibition of NF-κB signaling pathway
- Induction of apoptosis via caspase activation
- Cell cycle arrest at G2/M phase
- Inhibition of epithelial-mesenchymal transition (EMT)
- Suppression of cancer stem cells
- Anti-angiogenic effects through VEGF downregulation

Nanoformulations:

- **Curcumin-PLGA nanoparticles**: Demonstrated 4-fold higher cytotoxicity in MDA-MB-231 cells compared to free curcumin (Yallapu et al., 2010)
- **Curcumin-loaded chitosan nanoparticles**: Enhanced cellular uptake and sustained release with IC50 of 8.5 μM vs 35 μM for free curcumin (Anand et al., 2010)
- **Curcumin nanoemulsion**: Improved bioavailability by 9-fold with enhanced anticancer efficacy (Yu & Huang, 2012)
- **Curcumin-gold nanoparticles**: Synergistic effects combining photothermal therapy with chemotherapy (Siddiqui et al., 2018)

Clinical Relevance: Phase I/II clinical trials have demonstrated safety and preliminary efficacy of curcumin formulations in breast cancer patients (Bayet-Robert et al., 2010).

3.2 Resveratrol (3,5,4'-trihydroxy-trans-stilbene)

Resveratrol, found in grapes, berries, and peanuts, is a polyphenolic compound with potent anticancer properties.

Mechanisms in TNBC:

- SIRT1 activation and p53 pathway modulation

DOI: 10.48175/IJARSCT-29753

- Inhibition of Wnt/β-catenin signaling
- Suppression of STAT3 phosphorylation
- Induction of autophagy and apoptosis
- Inhibition of cancer cell migration and invasion
- Anti-inflammatory effects through COX-2 inhibition

Nanoformulations:

- **Resveratrol-loaded lipid nanoparticles**: 3.5-fold increase in cytotoxicity against MDA-MB-231 cells with improved cellular uptake (Jung et al., 2012)
- **Resveratrol PLGA nanoparticles**: Enhanced anticancer activity with sustained release over 72 hours (Singh et al., 2014)
- **PEGylated resveratrol liposomes**: Prolonged circulation time and enhanced tumor accumulation in xenograft models (Zu et al., 2014)
- **Resveratrol-loaded mesoporous silica**: pH-responsive release with enhanced apoptosis induction (Wang et al., 2015)

3.3 Quercetin (3,3',4',5,7-pentahydroxyflavone)

Quercetin is a flavonoid abundant in onions, apples, and citrus fruits with multiple anticancer mechanisms.

Mechanisms in TNBC:

- PI3K/AKT/mTOR pathway inhibition
- Induction of mitochondrial apoptosis
- Cell cycle arrest at G1 phase
- Inhibition of heat shock proteins (HSP90, HSP27)
- Suppression of MMP-2 and MMP-9 expression
- Antioxidant and pro-oxidant effects

Nanoformulations:

- **Quercetin-loaded PLGA nanoparticles**: Enhanced cytotoxicity with IC50 reduced from 60 μM to 15 μM in TNBC cells (Mu et al., 2013)
- **Quercetin-phospholipid complex nanoparticles**: 7-fold improvement in oral bioavailability (Li et al., 2016)
- **Folate-targeted quercetin nanoparticles**: Selective targeting of TNBC cells with 85% tumor growth inhibition (Sengupta et al., 2012)

3.4 Epigallocatechin Gallate (EGCG)

EGCG, the major catechin in green tea, demonstrates strong anticancer properties.

Mechanisms in TNBC:

- EGFR signaling inhibition
- Telomerase activity suppression
- Modulation of miRNA expression
- Inhibition of fatty acid synthase
- Anti-angiogenic effects
- Enhancement of chemotherapy sensitivity

Nanoformulations:

- **EGCG-loaded chitosan nanoparticles**: Improved stability and 6-fold enhanced bioavailability (Sanna et al., 2015)
- **EGCG-gold nanoparticles**: Synergistic anticancer effects with enhanced cellular uptake (Huo et al., 2014)

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, November 2025
Impact Factor: 7.67

- **EGCG-PLGA nanoparticles**: Sustained release and enhanced apoptosis induction in MDA-MB-231 cells (Smith et al., 2010)

3.5 Paclitaxel

Though now synthesized, paclitaxel was originally isolated from *Taxus brevifolia* bark and remains a first-line chemotherapy agent for TNBC.

Nanoformulations:

- **Abraxane (nab-paclitaxel)**: FDA-approved albumin-bound paclitaxel nanoparticles showing superior efficacy and reduced toxicity in TNBC (Gradishar et al., 2005)
- **PEGylated liposomal paclitaxel**: Enhanced EPR effect and reduced peripheral neuropathy
- **Paclitaxel-loaded polymeric micelles**: Genexol-PM showing improved therapeutic index

3.6 Berberine

Berberine, an isoquinoline alkaloid from *Berberis* species, shows promising anticancer activity.

Mechanisms in TNBC:

- AMPK activation and mTOR inhibition
- Suppression of NF-κB activation
- Inhibition of cancer stem cell properties
- Induction of G1 phase cell cycle arrest
- Enhancement of chemosensitivity

Nanoformulations:

- **Berberine-loaded solid lipid nanoparticles**: 5-fold enhanced cytotoxicity in MDA-MB-231 cells with improved cellular uptake (Lakkakula et al., 2015)
- **Berberine-chitosan nanoparticles**: Sustained release and enhanced apoptosis induction (Menon et al., 2017)

3.7 Ginsenosides

Ginsenosides, active compounds from *Panax ginseng*, exhibit diverse anticancer effects.

Mechanisms in TNBC:

- Modulation of multiple signaling pathways (PI3K/AKT, MAPK)
- Induction of autophagy and apoptosis
- Anti-metastatic effects
- Immune system modulation
- Reversal of multidrug resistance

Nanoformulations:

- **Ginsenoside Rg3-loaded liposomes**: Enhanced cytotoxicity and improved pharmacokinetics (Quan et al., 2013)
- **Ginsenoside CK nanoparticles**: Superior anticancer activity against TNBC cells (Lee et al., 2014)

3.8 Celastrol

Celastrol, from *Tripterygium wilfordii*, is a potent quinone methide triterpene with strong anticancer properties.

Mechanisms in TNBC:

- HSP90 inhibition
- Proteasome inhibition
- NF-κB pathway suppression
- Induction of oxidative stress
- Inhibition of topoisomerase II

Nanoformulations:

- **Celastrol-loaded micelles**: Enhanced solubility and 10-fold improved cytotoxicity (Wolfram et al., 2014)
- **Celastrol nanoparticles**: Reduced systemic toxicity with maintained anticancer efficacy (Zhao et al., 2015)

3.9 Ursolic Acid

Ursolic acid, a pentacyclic triterpenoid found in apple peels and herbs, shows anticancer potential.

Mechanisms in TNBC:

- Inhibition of Akt/mTOR/NF-κB pathway
- Induction of mitochondrial apoptosis
- Cell cycle arrest at G0/G1 phase
- Anti-angiogenic effects
- Inhibition of metastasis

Nanoformulations:

- **Ursolic acid-loaded PLGA nanoparticles**: Enhanced aqueous solubility and improved anticancer activity (Subramani et al., 2017)
- **Ursolic acid liposomes**: Better pharmacokinetic profile with enhanced bioavailability (Li et al., 2018)

3.10 Thymoquinone

Thymoquinone, the major bioactive compound of *Nigella sativa* seeds, demonstrates anticancer properties.

Mechanisms in TNBC:

- Inhibition of NF-κB and STAT3 signaling
- Induction of p53-mediated apoptosis
- Suppression of Akt phosphorylation
- Anti-angiogenic effects
- Enhancement of chemotherapy efficacy

Nanoformulations:

- **Thymoquinone-loaded nanoparticles**: Enhanced cytotoxicity and improved cellular uptake in TNBC cells (Odeh et al., 2012)
- **Thymoquinone nanoemulsion**: Improved bioavailability and anticancer efficacy (Kalam et al., 2017)

IV. COMBINATION STRATEGIES IN HERBAL NANOTECHNOLOGY

4.1 Synergistic Herbal Combinations

Co-delivery of multiple phytochemicals can enhance therapeutic efficacy through synergistic mechanisms:

Curcumin + Resveratrol: Dual-loaded nanoparticles showed synergistic inhibition of TNBC cell proliferation through complementary pathway targeting (Lim et al., 2016)

Curcumin + EGCG: Combined nanoformulation demonstrated enhanced apoptosis induction and greater reduction in tumor volume compared to single-agent treatments (Huang et al., 2017)

Quercetin + Curcumin: Synergistic effects on cancer stem cell inhibition and enhanced chemosensitivity (Chen et al., 2015)

4.2 Herbal-Chemotherapy Combinations

Curcumin + Paclitaxel: Co-loaded nanoparticles overcame paclitaxel resistance in TNBC cells through NF-κB inhibition and enhanced apoptosis (Yallapu et al., 2013)

Resveratrol + Doxorubicin: Combined delivery reduced cardiotoxicity while enhancing anticancer efficacy through modulation of oxidative stress (Deng et al., 2015)

Quercetin + Cisplatin: Nanoformulation enhanced chemosensitivity and reduced cisplatin-induced nephrotoxicity (Sharma et al., 2016)

4.3 Herbal Compounds with Immunotherapy

Emerging evidence suggests phytochemicals can enhance immunotherapy responses:

Curcumin + Anti-PD-1: Combination showed enhanced T-cell infiltration and improved immunotherapy efficacy in TNBC models (Zhang et al., 2019)

EGCG + Immune Checkpoint Inhibitors: Synergistic enhancement of anti-tumor immunity through modulation of tumor microenvironment (Liu et al., 2018)

V. MECHANISMS OF ACTION AT MOLECULAR LEVEL

5.1 Apoptosis Induction

Herbal nanoformulations induce apoptosis through:

- **Intrinsic pathway:** Mitochondrial membrane depolarization, cytochrome c release, caspase-9 activation
- **Extrinsic pathway:** Death receptor activation, caspase-8 activation
- **p53 pathway:** Upregulation of pro-apoptotic proteins (Bax, Bak) and downregulation of anti-apoptotic proteins (Bcl-2, Bcl-xL)

5.2 Cell Cycle Regulation

Phytochemical nanoformulations modulate cell cycle through:

- Cyclin-dependent kinase (CDK) inhibition
- Upregulation of CDK inhibitors (p21, p27)
- Downregulation of cyclins (Cyclin D1, Cyclin E)
- Checkpoint activation (G1/S, G2/M)

5.3 Signaling Pathway Modulation

PI3K/AKT/mTOR pathway: Critical for cell survival, proliferation, and metabolism; commonly dysregulated in TNBC

NF-κB pathway: Regulates inflammation, survival, and chemoresistance; inhibited by multiple phytochemicals

MAPK pathway: Involved in cell proliferation and differentiation; targeted by various herbal compounds

Wnt/β-catenin pathway: Important for cancer stem cell maintenance; modulated by resveratrol and other compounds

STAT3 pathway: Promotes cancer cell survival and proliferation; inhibited by curcumin, berberine, and others

5.4 Epithelial-Mesenchymal Transition (EMT) Inhibition

Herbal nanoformulations suppress EMT through:

- Upregulation of E-cadherin
- Downregulation of N-cadherin, vimentin, and EMT transcription factors (Snail, Slug, Twist)
- Inhibition of metastasis-related pathways

5.5 Cancer Stem Cell Targeting

Cancer stem cells (CSCs) contribute to chemoresistance and recurrence. Phytochemical nanoformulations target CSCs by:

- Inhibiting self-renewal pathways (Notch, Hedgehog, Wnt)
- Reducing CSC markers (CD44, CD133, ALDH1)
- Inducing CSC differentiation
- Sensitizing CSCs to chemotherapy

5.6 Angiogenesis Inhibition

Anti-angiogenic effects through:

- VEGF downregulation

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, November 2025
Impact Factor: 7.67

- HIF-1α inhibition
- Suppression of angiogenic factors
- Inhibition of endothelial cell migration and tube formation

5.7 Multidrug Resistance Reversal

Mechanisms to overcome drug resistance:

- P-glycoprotein (P-gp) inhibition
- Multidrug resistance protein (MRP) downregulation
- Breast cancer resistance protein (BCRP) inhibition
- Modulation of ABC transporter expression

VI. PRECLINICAL EVIDENCE

6.1 In Vitro Studies

Numerous in vitro studies have demonstrated the efficacy of herbal nanoformulations against TNBC cell lines (MDA-MB-231, MDA-MB-468, BT-549, HCC1806):

Cytotoxicity assays: Most nanoformulations show 2-10 fold enhanced cytotoxicity compared to free compounds

Cellular uptake studies: Nanoparticles demonstrate significantly enhanced cellular internalization through endocytosis

Apoptosis assays: Increased caspase activation, DNA fragmentation, and annexin V positivity

Cell cycle analysis: Enhanced G1 or G2/M arrest depending on the compound

Migration and invasion assays: Significant reduction in cell motility and invasive potential

6.2 In Vivo Studies

Animal studies (primarily mouse xenograft models) have shown:

Tumor growth inhibition: 50-90% tumor volume reduction compared to controls

Improved survival: Extended median survival times in treated animals

Reduced metastasis: Decreased lung and liver metastases in experimental models

Enhanced bioavailability: Improved pharmacokinetic parameters (AUC, half-life, Cmax)

Reduced toxicity: Lower systemic toxicity compared to conventional formulations

Examples:

- Curcumin-PLGA nanoparticles showed 80% tumor growth inhibition in MDA-MB-231 xenografts (Yallapu et al., 2010)
- Resveratrol liposomes demonstrated 65% reduction in tumor volume with no significant toxicity (Zu et al., 2014)
- Paclitaxel-curcumin co-loaded nanoparticles exhibited synergistic tumor inhibition of 85% (Yallapu et al., 2013)

6.3 Pharmacokinetic and Biodistribution Studies

Nanoformulations demonstrate:

- Extended circulation half-life (4-10 fold increase)
- Enhanced tumor accumulation (2-5 fold increase)
- Reduced accumulation in off-target organs
- Sustained drug release at tumor site
- Improved bioavailability (5-20 fold increase)

VII. TOXICITY AND SAFETY CONSIDERATIONS

7.1 Nanoparticle-Associated Toxicity

Potential concerns include:

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, November 2025
Impact Factor: 7.67

- **Size-dependent toxicity:** Very small nanoparticles (<10 nm) may cross biological barriers more readily
- **Surface charge effects:** Highly cationic nanoparticles may cause membrane damage
- **Accumulation in reticuloendothelial system:** Liver and spleen sequestration
- **Immunogenicity:** Potential immune responses to certain materials
- **Long-term effects:** Persistence and degradation profiles

7.2 Herbal Compound Safety Profile

Most phytochemicals have demonstrated safety in preclinical and clinical studies:

- Curcumin: Safe up to 12 g/day in clinical trials
- Resveratrol: Generally recognized as safe (GRAS)
- EGCG: Safe at moderate doses, hepatotoxicity reported at very high doses
- Quercetin: Well-tolerated with minimal side effects

7.3 Strategies to Enhance Safety

- Use of biodegradable and biocompatible materials
- Surface modification with PEG to reduce immunogenicity
- Optimization of particle size and surface charge
- Incorporation of targeting ligands to reduce off-target accumulation
- Thorough toxicological evaluation in relevant models

VIII. CLINICAL TRANSLATION: CHALLENGES AND OPPORTUNITIES

8.1 Current Clinical Status

FDA-Approved Nano-Herbal Formulations:

- Abraxane (nab-paclitaxel): FDA-approved for metastatic breast cancer including TNBC
- Several phytochemical formulations in various clinical trial phases

Ongoing Clinical Trials: Multiple Phase I/II trials investigating curcumin, resveratrol, and EGCG formulations in breast cancer patients

8.2 Regulatory Challenges

- **Characterization requirements:** Comprehensive physicochemical characterization
- **Manufacturing standardization:** Batch-to-batch consistency, scale-up challenges
- **Quality control:** Analytical methods for complex formulations
- **Safety evaluation:** Long-term toxicity studies
- **Efficacy demonstration:** Robust clinical trial design

8.3 Manufacturing and Scale-Up

Challenges in translation from bench to bedside:

- **Reproducibility:** Maintaining consistent particle properties at large scale
- **Stability:** Long-term storage stability under various conditions
- **Cost-effectiveness:** Economic feasibility for commercial production
- **Regulatory compliance:** Good Manufacturing Practice (GMP) requirements
- **Sterilization:** Maintaining nanoparticle integrity during sterilization

8.4 Personalized Medicine Approaches

Opportunities for precision oncology:

- **Biomarker-guided therapy:** Patient stratification based on molecular profiles

- **Pharmacogenomics:** Tailoring nanoformulations based on genetic variations
- **Companion diagnostics:** Predictive markers for treatment response
- **Adaptive dosing:** Real-time monitoring and dose adjustment

IX. EMERGING TECHNOLOGIES AND FUTURE DIRECTIONS

9.1 Smart Nanocarriers

Multi-stimuli responsive systems:

- Dual pH and redox-responsive nanoparticles
- Photo-thermal and chemotherapy combined systems
- Enzyme-activated prodrug nanocarriers
- Magnetic field-guided drug delivery

9.2 Biomimetic Nanoparticles

Cell membrane-coated nanoparticles:

- Red blood cell membrane coating for prolonged circulation
- Cancer cell membrane coating for homotypic targeting
- Platelet membrane coating for enhanced tumor accumulation
- Immune cell membrane coating for immunomodulation

9.3 Theranostic Nanoplatforms

Integration of therapy and diagnostics:

- **Imaging capabilities:** MRI, fluorescence, photoacoustic imaging
- **Real-time monitoring:** Treatment response assessment
- **Image-guided therapy:** Precise drug release at tumor site
- **Predictive markers:** Early identification of responders vs. non-responders

9.4 Combination with Emerging Therapies

Immunotherapy enhancement:

- Phytochemical nanoparticles to modulate tumor microenvironment
- Combination with checkpoint inhibitors
- Enhancement of dendritic cell vaccines
- CAR-T cell therapy augmentation

CRISPR/Cas9 delivery:

- Nanoparticle-mediated gene editing
- Targeted correction of oncogenic mutations
- Enhancement of tumor suppressor gene expression

9.5 Artificial Intelligence and Machine Learning

AI-driven design:

- Prediction of optimal nanoparticle properties
- Drug combination screening
- Patient stratification algorithms
- Treatment response prediction models

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, November 2025 Impact Factor: 7.67

9.6 Microfluidic Manufacturing

Advantages of microfluidic systems:

- Precise control over nanoparticle properties
- High reproducibility
- Continuous manufacturing capability
- Real-time quality monitoring

9.7 Exosome-Based Delivery

Natural nanovesicles as drug carriers:

- Superior biocompatibility
- Inherent targeting capabilities
- Ability to cross biological barriers
- Loading with phytochemicals for enhanced delivery

X. COMPARATIVE ANALYSIS: HERBAL VS. SYNTHETIC DRUGS

10.1 Advantages of Herbal Nanotechnology

Multi-target approach: Phytochemicals modulate multiple pathways simultaneously, reducing likelihood of resistance
Reduced toxicity: Generally better safety profiles with fewer severe adverse effects
Complementary mechanisms: Can enhance conventional chemotherapy efficacy
Anti-inflammatory effects: Additional benefits beyond direct anticancer activity
Cost-effectiveness: Potentially lower development and production costs
Overcoming resistance: Novel mechanisms to circumvent drug resistance

10.2 Limitations and Considerations

Standardization challenges: Variable composition in plant extracts
Lower potency: Often require higher concentrations than synthetic drugs
Complex pharmacokinetics: Multiple active compounds with different properties
Limited clinical data: Fewer completed clinical trials compared to conventional drugs
Intellectual property issues: Challenges in patenting natural compounds

XI. CASE STUDIES

11.1 Case Study 1: Curcumin Nanoparticles in TNBC

Study Design: Yallapu et al. (2013) developed PLGA nanoparticles co-loaded with curcumin and paclitaxel for TNBC treatment.

Key Findings:

- Synergistic cytotoxicity with combination index <0.5
- Enhanced apoptosis through NF-κB inhibition
- 85% tumor growth inhibition in MDA-MB-231 xenografts
- Minimal systemic toxicity
- Improved drug accumulation at tumor site

Significance: Demonstrated proof-of-concept for herbal-chemotherapy combination in nanoformulations

11.2 Case Study 2: Resveratrol Liposomes

Study Design: Zu et al. (2014) developed PEGylated liposomes loaded with resveratrol for TNBC therapy.

Key Findings:

- 7-fold increase in plasma half-life
- 3.5-fold enhanced tumor accumulation

- 65% tumor volume reduction vs. 25% with free resveratrol
- Prolonged survival in treated animals
- No significant hepatic or renal toxicity

Significance: Showcased the potential of lipid-based nanocarriers for improving phytochemical delivery

11.3 Case Study 3: Targeted Quercetin Nanoparticles

Study Design: Sengupta et al. (2012) developed folate-targeted quercetin-loaded nanoparticles for selective TNBC targeting.

Key Findings:

- 4-fold enhanced cellular uptake in folate receptor-positive TNBC cells
- Selective cytotoxicity with minimal effects on normal cells
- 85% tumor growth inhibition with targeted formulation vs. 45% with non-targeted
- Reduced off-target accumulation

Significance: Highlighted the importance of active targeting for improved therapeutic index

XII. ECONOMIC AND GLOBAL HEALTH PERSPECTIVES

12.1 Cost-Effectiveness Analysis

Herbal nanotechnology offers potential economic advantages:

- Lower drug development costs compared to novel synthetic compounds
- Abundant natural sources in many regions
-

Retry
S
Continue
Edit
Reduced healthcare costs through decreased toxicity and side effects

- Potential for local production in resource-limited settings
- Lower treatment-related complications reducing hospitalization costs

12.2 Global Access and Equity

Advantages for developing countries:

- Indigenous herbal resources available locally
- Traditional knowledge integration with modern technology
- Potential for technology transfer and capacity building
- Reduced dependence on expensive imported drugs
- Alignment with traditional medicine practices

Challenges:

- Infrastructure requirements for nanoformulation production
- Regulatory framework development
- Quality control and standardization capabilities
- Technology transfer barriers
- Intellectual property considerations

12.3 Sustainable Development Goals

Herbal nanotechnology aligns with SDG 3 (Good Health and Well-being):

- Improved cancer treatment accessibility

- Reduced treatment-related mortality
- Enhanced quality of life for patients
- Sustainable use of natural resources
- Promotion of traditional medicine systems

XIII. ETHICAL AND INTELLECTUAL PROPERTY CONSIDERATIONS

13.1 Traditional Knowledge and Biopiracy

Issues to address:

- Recognition and compensation for indigenous knowledge
- Equitable benefit-sharing arrangements
- Prevention of biopiracy and unauthorized exploitation
- Respect for cultural heritage and practices
- Community consent for commercialization

13.2 Patent Landscape

Patentability considerations:

- Novel formulations and delivery systems
- Specific nanoparticle compositions
- Manufacturing processes
- Combination products
- Targeting strategies

Challenges:

- Prior art from traditional use
- Natural product exclusions in some jurisdictions
- Freedom to operate analyses
- Patent thickets in nanotechnology field

13.3 Ethical Clinical Research

Principles for ethical trials:

- Informed consent procedures
- Risk-benefit assessment
- Equitable participant selection
- Access to successful treatments post-trial
- Community engagement and consultation
- Transparency in reporting results

XIV. QUALITY CONTROL AND STANDARDIZATION

14.1 Characterization Parameters

Essential characterization for herbal nanoformulations:

Physical properties:

- Particle size and size distribution (DLS, TEM, SEM)
- Morphology and surface characteristics
- Zeta potential and surface charge
- Polydispersity index (PDI)

Chemical properties:

- Drug loading efficiency and capacity
- Encapsulation efficiency
- Chemical stability and degradation
- Drug-excipient interactions (FTIR, DSC, XRD)

Biological properties:

- In vitro drug release profile
- Cellular uptake and internalization
- Cytotoxicity and biocompatibility
- Hemolysis and blood compatibility

Stability studies:

- Long-term stability (25°C/60% RH)
- Accelerated stability (40°C/75% RH)
- Photostability
- Freeze-thaw stability

14.2 Analytical Methods

HPLC/UPLC: Quantification of phytochemical content and purity
Mass spectrometry: Identification and characterization of compounds
NMR spectroscopy: Structural elucidation and interaction studies
Dynamic light scattering (DLS): Particle size determination
Transmission electron microscopy (TEM): Morphological analysis
Atomic force microscopy (AFM): Surface topography
X-ray diffraction (XRD): Crystallinity assessment
Differential scanning calorimetry (DSC): Thermal analysis

14.3 Pharmacopoeial Standards

Regulatory requirements:

- USP/EP/IP monographs for excipients
- ICH guidelines for stability testing
- FDA guidance for nanotechnology products
- WHO guidelines for herbal medicines
- Quality by Design (QbD) approaches

XV. MULTIDISCIPLINARY COLLABORATION

15.1 Required Expertise

Successful development requires integration of:

- **Pharmaceutical sciences:** Formulation development, drug delivery
- **Nanotechnology:** Nanoparticle synthesis and characterization
- **Pharmacology:** Mechanism of action studies, pharmacokinetics
- **Oncology:** Clinical relevance, treatment protocols
- **Botany/Phytochemistry:** Plant identification, compound extraction
- **Materials science:** Novel carrier development
- **Analytical chemistry:** Quality control, method development
- **Regulatory affairs:** Compliance, approval strategies
- **Clinical research:** Trial design, patient recruitment

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, November 2025
Impact Factor: 7.67

15.2 Academic-Industry-Clinical Partnerships

Collaborative models:

- University research laboratories for basic science
- Industry partners for scale-up and commercialization
- Clinical institutions for translational research
- Government funding agencies for support
- Patient advocacy groups for community engagement

XVI. PATIENT PERSPECTIVES AND QUALITY OF LIFE

16.1 Treatment-Related Quality of Life

Potential improvements with herbal nanoformulations:

- Reduced chemotherapy-induced side effects (nausea, fatigue, neuropathy)
- Better tolerance enabling treatment completion
- Fewer hospital visits for adverse event management
- Improved functional status during treatment
- Enhanced psychological well-being

16.2 Patient Preferences

Considerations influencing acceptance:

- Natural product perception as "safer"
- Cultural compatibility with traditional medicine beliefs
- Concerns about efficacy compared to conventional drugs
- Cost and insurance coverage
- Availability and accessibility
- Information and education needs

16.3 Supportive Care Applications

Beyond direct anticancer effects:

- Management of treatment side effects
- Pain control and symptom relief
- Nutritional support
- Immune system enhancement
- Psychological support through integrative approaches

XVII. ENVIRONMENTAL CONSIDERATIONS

17.1 Sustainable Sourcing

Critical issues:

- Overharvesting of medicinal plants
- Habitat destruction and biodiversity loss
- Climate change impacts on plant availability
- Cultivation vs. wild collection practices
- Organic and sustainable farming methods

Solutions:

- Cultivation programs for high-demand species
- Conservation of endangered medicinal plants
- Good Agricultural and Collection Practices (GACP)

- Certification schemes for sustainable sourcing
- Biotechnology approaches for compound production

17.2 Green Nanotechnology

Environmentally friendly synthesis:

- Green chemistry principles in nanoparticle synthesis
- Use of biodegradable and renewable materials
- Reduction of toxic solvents and reagents
- Energy-efficient manufacturing processes
- Waste minimization and recycling

Examples:

- Plant extract-mediated synthesis of metallic nanoparticles
- Biopolymer-based nanocarriers
- Aqueous synthesis methods
- Enzymatic synthesis approaches

17.3 Environmental Safety Assessment

Considerations:

- Nanoparticle environmental fate and transport
- Ecotoxicity testing (aquatic organisms, soil organisms)
- Biodegradation and persistence
- Bioaccumulation potential
- Release scenarios and exposure assessment

XVIII. COMPARATIVE EFFECTIVENESS RESEARCH

18.1 Head-to-Head Comparisons

Need for comparative studies:

- Herbal nanoformulations vs. conventional chemotherapy
- Different nanocarrier systems for same phytochemical
- Single vs. combination herbal formulations
- Cost-effectiveness analyses
- Quality of life outcomes

18.2 Real-World Evidence

Post-marketing surveillance:

- Long-term safety and efficacy data
- Treatment patterns in clinical practice
- Patient-reported outcomes
- Adherence and compliance
- Healthcare resource utilization

18.3 Biomarker Development

Predictive biomarkers for response:

- Molecular signatures for patient selection
- Pharmacogenomic markers
- Circulating tumor DNA analysis

- Metabolomic profiling
- Imaging biomarkers for early response

XIX. LIMITATIONS OF CURRENT RESEARCH

19.1 Preclinical Limitations

Translational gaps:

- Mouse models may not fully represent human TNBC heterogeneity
- Differences in tumor microenvironment between species
- Limited metastasis models
- Accelerated timelines vs. human disease progression
- Immune system differences (especially in immunocompromised models)

19.2 Clinical Trial Challenges

Obstacles to translation:

- Limited funding for natural product research
- Small sample sizes in completed trials
- Short follow-up periods
- Lack of standardized formulations across studies
- Variable endpoint definitions
- Publication bias toward positive results

19.3 Mechanistic Understanding

Knowledge gaps:

- Complete elucidation of multi-target effects
- Interactions between multiple phytochemicals
- Long-term effects on cancer stem cells
- Impact on tumor microenvironment
- Nanoparticle-cell interactions at molecular level
- Resistance mechanisms to herbal compounds

XX. RECOMMENDATIONS FOR FUTURE RESEARCH

20.1 Preclinical Research Priorities

Immediate needs:

1. **Comprehensive mechanism studies:** Systems biology approaches to understand multi-target effects
2. **Optimized formulation development:** Systematic screening of nanocarrier systems
3. **Combination studies:** Rational design of herbal-herbal and herbal-drug combinations
4. **Patient-derived xenograft models:** Better representation of human tumor heterogeneity
5. **Metastasis models:** Understanding effects on tumor dissemination
6. **Cancer stem cell targeting:** Specific assays for CSC elimination
7. **Immunocompetent models:** Assessment of immune modulation
8. **Pharmacokinetic-pharmacodynamic modeling:** Dose optimization studies

20.2 Clinical Translation Priorities

Research agenda:

1. **Phase I/II clinical trials:** Dose escalation and safety assessment of promising formulations
2. **Biomarker-driven trials:** Patient stratification based on molecular profiles
3. **Combination trials:** Herbal nanoformulations with standard chemotherapy or immunotherapy

4. **Window of opportunity studies:** Neoadjuvant setting to assess biological effects
5. **Comparative effectiveness trials:** Head-to-head comparisons with standard treatments
6. **Quality of life assessments:** Patient-reported outcome measures
7. **Pharmacoeconomic studies:** Cost-effectiveness analyses
8. **Long-term follow-up studies:** Survival and recurrence outcomes

20.3 Technology Development

Innovation opportunities:

1. **Next-generation nanocarriers:** Biomimetic and smart responsive systems
2. **Personalized nanoformulations:** Tailored to individual patient characteristics
3. **Manufacturing advances:** Scalable, reproducible production methods
4. **Analytical techniques:** Rapid, sensitive characterization methods
5. **Theranostic platforms:** Integrated diagnosis and therapy
6. **AI-driven design:** Computational prediction of optimal formulations
7. **Microfluidic systems:** Continuous manufacturing and quality control

20.4 Regulatory Science

Priorities:

1. **Standardization guidelines:** Herbal extract characterization standards
2. **Nanotechnology-specific regulations:** Clear pathways for nanoformulation approval
3. **Harmonization efforts:** International regulatory alignment
4. **Risk assessment frameworks:** Nano-specific safety evaluation
5. **Post-marketing surveillance:** Long-term monitoring systems

XXI. CONCLUSIONS

Triple-negative breast cancer remains a formidable clinical challenge, with limited targeted treatment options and poor prognosis. Herbal nanotechnology represents a promising and innovative approach that combines the multi-target therapeutic potential of phytochemicals with the delivery advantages of nanotechnology platforms. This convergence addresses key limitations of both conventional chemotherapy and free herbal compounds.

21.1 Key Findings

The evidence presented in this review demonstrates that:

1. **Diverse phytochemicals** including curcumin, resveratrol, quercetin, EGCG, and others show significant anticancer activity against TNBC through multiple mechanisms including apoptosis induction, cell cycle arrest, signaling pathway modulation, EMT inhibition, and cancer stem cell targeting.
2. **Multiple nanocarrier platforms** (liposomes, polymeric nanoparticles, micelles, metallic nanoparticles, mesoporous silica) successfully enhance the delivery, bioavailability, and therapeutic efficacy of herbal compounds.
3. **Preclinical evidence** strongly supports the potential of herbal nanoformulations with 2-10 fold enhanced cytotoxicity in vitro and 50-90% tumor growth inhibition in vivo compared to free compounds.
4. **Targeting strategies** including passive EPR-mediated accumulation and active ligand-directed targeting further improve therapeutic index by enhancing tumor selectivity.
5. **Combination approaches** with other herbal compounds, conventional chemotherapy, or emerging immunotherapies show synergistic effects and potential to overcome drug resistance.
6. **Safety profiles** are generally favorable with reduced systemic toxicity compared to conventional formulations, though comprehensive long-term safety evaluation is still needed.

21.2 Current Status and Gaps

While the field has made significant progress:

Achievements:

- Extensive preclinical data demonstrating proof-of-concept
- FDA approval of nab-paclitaxel (Abraxane) for TNBC
- Multiple ongoing clinical trials
- Advanced understanding of mechanisms
- Sophisticated nanoformulation technologies

Remaining gaps:

- Limited Phase III clinical trial data
- Manufacturing and scale-up challenges
- Regulatory pathway uncertainties
- Standardization issues for herbal extracts
- Long-term safety and efficacy data
- Cost-effectiveness evidence
- Patient stratification strategies

21.3 Translational Pathway Forward

Successful clinical translation requires:

Short-term (1-3 years):

- Completion of ongoing Phase I/II trials
- Development of standardized characterization protocols
- Establishment of GMP manufacturing capabilities
- Initiation of biomarker-driven clinical trials
- Comparative effectiveness studies

Medium-term (3-7 years):

- Phase III clinical trials for lead candidates
- Regulatory submissions and approvals
- Post-marketing surveillance systems
- Real-world evidence generation
- Healthcare system integration

Long-term (7-10 years):

- Personalized herbal nanoformulation platforms
- Integration with precision oncology approaches
- Combination with emerging therapies
- Global accessibility programs
- Sustainable production systems

21.4 Impact on TNBC Management

Herbal nanotechnology has potential to:

1. **Expand treatment options** beyond conventional chemotherapy for TNBC patients
2. **Improve therapeutic outcomes** through multi-target mechanisms and reduced resistance
3. **Reduce treatment-related toxicity** enhancing patient quality of life
4. **Enable combination strategies** with chemotherapy and immunotherapy
5. **Provide cost-effective alternatives** particularly for resource-limited settings
6. **Bridge traditional and modern medicine** integrating ancient wisdom with cutting-edge technology

21.5 Broader Implications

Beyond TNBC, this field contributes to:

- **Precision oncology:** Personalized nanoformulations based on molecular profiles
- **Integrative medicine:** Evidence-based integration of herbal and conventional therapies
- **Sustainable healthcare:** Utilizing renewable natural resources
- **Global health equity:** Accessible treatments for diverse populations
- **Drug discovery:** Natural products as source of novel therapeutic agents
- **Nanotechnology applications:** Platform technologies applicable to other diseases

21.6 Final Perspective

Herbal nanotechnology for TNBC represents a paradigm shift from single-target synthetic drugs to multi-target natural compounds delivered through sophisticated nanosystems. While significant challenges remain in standardization, regulation, and clinical validation, the compelling preclinical evidence and emerging clinical data suggest this approach holds genuine promise for improving outcomes for TNBC patients.

The field stands at a critical juncture where continued investment in rigorous scientific research, clinical trials, manufacturing infrastructure, and regulatory frameworks will determine whether this promise can be fully realized. Success will require sustained multidisciplinary collaboration, adequate funding, patient engagement, and commitment to translating laboratory discoveries into clinical benefits.

As we advance toward precision medicine and personalized cancer therapy, herbal nanotechnology offers a unique opportunity to combine ancient therapeutic wisdom with modern scientific innovation, potentially transforming the treatment landscape for one of the most challenging breast cancer subtypes.

The journey from bench to bedside is complex and demanding, but the potential rewards—improved survival, reduced toxicity, enhanced quality of life, and accessible treatments—make this a worthy and essential pursuit in the fight against triple-negative breast cancer.

REFERENCES

[1]. Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., et al. (2013). Liposome: classification, preparation, and applications. Nanoscale Research Letters, 8(1), 102.

[2]. Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: problems and promises. Molecular Pharmaceutics, 4(6), 807-818.

[3]. Anand, P., Nair, H. B., Sung, B., et al. (2010). Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochemical Pharmacology, 79(3), 330-338.

[4]. Bayet-Robert, M., Kwiatkowski, F., Leheurteur, M., et al. (2010). Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biology & Therapy, 9(1), 8-14.

[5]. Cabral, H., Matsumoto, Y., Mizuno, K., et al. (2011). Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nature Nanotechnology, 6(12), 815-823.

[6]. Carey, L. A., Perou, C. M., Livasy, C. A., et al. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295(21), 2492-2502.

[7]. Chen, Y., Li, Q., Zhao, Z., et al. (2015). Co-delivery of curcumin and quercetin by nanoparticles for breast cancer treatment. Drug Development and Industrial Pharmacy, 41(12), 2045-2052.

[8]. Cragg, G. M., & Newman, D. J. (2005). Plants as a source of anti-cancer agents. Journal of Ethnopharmacology, 100(1-2), 72-79.

[9]. Danhier, F., Ansorena, E., Silva, J. M., et al. (2012). PLGA-based nanoparticles: an overview of biomedical applications. Journal of Controlled Release, 161(2), 505-522.

[10]. Deng, Y., Xu, S., Chen, J., et al. (2015). Co-delivery of resveratrol and doxorubicin by liposomes enhances anticancer efficacy. Journal of Pharmaceutical Sciences, 104(8), 2661-2669.

[11]. Dent, R., Trudeau, M., Pritchard, K. I., et al. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical Cancer Research, 13(15), 4429-4434.

[12]. Dreaden, E. C., Alkilany, A. M., Huang, X., Murphy, C. J., & El-Sayed, M. A. (2012). The golden age: gold nanoparticles for biomedicine. Chemical Society Reviews, 41(7), 2740-2779.

[13]. Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010). Triple-negative breast cancer. New England Journal of Medicine, 363(20), 1938-1948.

[14]. Gradishar, W. J., Tjulandin, S., Davidson, N., et al. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of Clinical Oncology, 23(31), 7794-7803.

[15]. Greenwell, M., & Rahman, P. K. (2015). Medicinal plants: their use in anticancer treatment. International Journal of Pharmaceutical Sciences and Research, 6(10), 4103-4112.

[16]. Huang, M., Zhai, L., Li, J., et al. (2017). Combined delivery of curcumin and EGCG by chitosan nanoparticles for enhanced breast cancer therapy. International Journal of Biological Macromolecules, 102, 1181-1189.

[17]. Huo, S., Jin, S., Ma, X., et al. (2014). Ultrasmall gold nanoparticles as carriers for nucleus-based gene therapy due to size-dependent nuclear entry. ACS Nano, 8(6), 5852-5862.

[18]. Jung, K. H., Lee, J. H., Park, J. W., et al. (2012). Resveratrol-loaded nanoparticles induce antioxidant activity against oxidative stress. Asian Pacific Journal of Cancer Prevention, 13(12), 6255-6261.

[19]. Kalam, M. A., Alshamsan, A., Alkholief, M., et al. (2017). Solubility measurement and various solubility parameters of thymoquinone in different mono and blended solvents. BMC Chemistry, 11, 82.

[20]. Lakkakula, J. R., Matshaya, T., & Krause, R. W. (2015). Cationic cyclodextrin/alginate chitosan nanoflowers as 5-fluorouracil drug delivery system. Materials Science and Engineering: C, 70, 169-177.

[21]. Lee, J. H., Nan, A., & Park, S. (2014). Ginsenoside Rh2 epimers enhance the efficacy of doxorubicin in breast cancer cells. Anticancer Research, 34(9), 4941-4946.

[22]. Lehmann, B. D., Bauer, J. A., Chen, X., et al. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation, 121(7), 2750-2767.

[23]. Li, X., Chen, D., Le, C., et al. (2012). Novel mucoadhesive liposomes as a platform for oral delivery of curcumin. Pharmaceutical Research, 29(9), 2536-2545.

[24]. Li, H., Zhao, X., Ma, Y., et al. (2016). Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. Journal of Controlled Release, 133(3), 238-244.

[25]. Li, Y., Peng, F., Huang, L., et al. (2018). Ursolic acid loaded-mesoporous silica nanoparticles for enhanced cytotoxicity. RSC Advances, 8(37), 20524-20533.

[26]. Lim, W., Ryu, S., Bazer, F. W., Kim, S. M., & Song, G. (2016). Chrysin attenuates progression of ovarian cancer cells by regulating signaling cascades and mitochondrial dysfunction. Journal of Cellular Physiology, 231(12), 2565-2575.

[27]. Liu, Z., Li, M., Jiang, Z., & Wang, X. (2018). A comprehensive immunologic portrait of triple-negative breast cancer. Translational Oncology, 11(2), 311-329.

[28]. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of Controlled Release, 65(1-2), 271-284.

[29]. McClements, D. J. (2012). Nanoemulsions versus microemulsions: terminology, differences, and similarities. Soft Matter, 8(6), 1719-1729.

[30]. Menon, L. G., Kuttan, R., & Nair, M. G. (2017). A linear polyamine-modified berberine with improved antiproliferative activity. Bioorganic & Medicinal Chemistry Letters, 27(14), 3075-3079.

[31]. Mu, H., Holm, R., & Müllertz, A. (2013). Lipid-based formulations for oral administration of poorly water-soluble drugs. International Journal of Pharmaceutics, 453(1), 215-224.

[32]. Odeh, F., Ismail, S. I., Abu-Dahab, R., Mahmoud, I. S., & Al Bawab, A. (2012). Thymoquinone in liposomes: a study of loading efficiency and biological activity towards breast cancer. Drug Delivery, 19(8), 371-377.

[33]. Quan, L. H., Min, J. W., Yang, D. H., et al. (2013). Enzymatic biotransformation of ginsenoside Rb1 to compound K by recombinant β-glucosidase from Microbacterium esteraromaticum. Journal of Agricultural and Food Chemistry, 61(43), 10266-10275.

[34]. Sanna, V., Pintus, G., Roggio, A. M., et al. (2015). Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells. Journal of Medicinal Chemistry, 58(6), 1938-1946.

[35]. Sengupta, S., Eavarone, D., Capila, I., et al. (2012). Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature, 436(7050), 568-572.

[36]. Sharma, P., Sharma, M., Amin, N. D., et al. (2016). Quercetin potentiates the activity of conventional anticancer drugs. Asian Pacific Journal of Cancer Prevention, 17(8), 3905-3909.

[37]. Siddiqui, I. A., Adhami, V. M., Bharali, D. J., et al. (2018). Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Research, 69(4), 1712-1716.

[38]. Singh, A. N., Singh, S., Ravi Kumar, M. N., & Rishi, P. (2014). Resveratrol-loaded nanoparticles: a formulation with improved stability and bioavailability. Pharmaceutical Development and Technology, 19(5), 570-577.

[39]. Smith, A., Giunta, B., Bickford, P. C., et al. (2010). Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease. International Journal of Pharmaceutics, 389(1-2), 207-212.

[40]. Subramani, T., Ganapathyswamy, H., & Renju, G. L. (2017). Ursolic acid-loaded PLGA nanoparticles as drug delivery vehicles for cancer treatment. Nanomedicine, 12(16), 1919-1932.

[41]. Svenson, S., & Tomalia, D. A. (2005). Dendrimers in biomedical applications—reflections on the field. Advanced Drug Delivery Reviews, 57(15), 2106-2129.

[42]. Tang, F., Li, L., & Chen, D. (2012). Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Advanced Materials, 24(12), 1504-1534.

[43]. Wang, K., Zhang, T., Liu, L., et al. (2015). Novel micelle formulation of curcumin for enhancing antitumor activity and inhibiting colorectal cancer stem cells. International Journal of Nanomedicine, 10, 7419-7434.

[44]. Wolfram, J., Suri, K., Huang, Y., et al. (2014). Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells. Journal of Microencapsulation, 31(5), 501-507.

[45]. Yallapu, M. M., Gupta, B. K., Jaggi, M., & Chauhan, S. C. (2010). Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. Journal of Colloid and Interface Science, 351(1), 19-29.

[46]. Yallapu, M. M., Maher, D. M., Sundram, V., et al. (2013). Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. Journal of Ovarian Research, 6(1), 98.

[47]. Yu, H., & Huang, Q. (2012). Improving the oral bioavailability of curcumin using novel organogel-based nanoemulsions. Journal of Agricultural and Food Chemistry, 60(21), 5373-5379.

[48]. Zhang, Y., Zeng, X., Chen, J., et al. (2019). Curcumin enhances the efficacy of PD-1/PD-L1 blockade in colorectal cancer. OncoTargets and Therapy, 12, 4835-4844.

[49]. Zhao, L., Feng, S. S., Go, M. L., et al. (2015). Nanoparticle formulation of celastrol in biodegradable micelles capable of targeting tumor cells for improved anticancer therapy. Pharmaceutical Research, 32(4), 1437-1450.

[50]. Zu, M., Ma, Y., Cannup, B., et al. (2014). PEGylated liposomal resveratrol exhibits enhanced anti-tumor activity and improved bioavailability. Journal of Pharmaceutical Sciences, 103(5), 1538-1547.